Sealbond Ltd

CIK: 0002040446

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)2 (66.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

DWTX

Dogwood Therapeutics, Inc.

Director10% Owner

Discretionary Trading P&L

Holdings

Transaction History (3 total)

DWTX
Dogwood Therapeutics, Inc.
Oct 26, 2026
Award(A)
Direct
4.1M shares at avg. $1.22$5.0M
DWTX
Dogwood Therapeutics, Inc.
Nov 21, 2025
Conversion(C)
Direct
21.6M shares-
DWTX
Dogwood Therapeutics, Inc.
Nov 21, 2025
Conversion(C)
Indirect
2.8M shares-

		Type	Shares	Price		Ownership
Oct 26, 2026	DWTX Dogwood Therapeutics, Inc.	Award(A)	4,098,360	$1.22	$4,999,999	Direct
Nov 21, 2025	DWTX Dogwood Therapeutics, Inc.	Conversion(C)	21,610,950	-	-	Direct
Nov 21, 2025	DWTX Dogwood Therapeutics, Inc.	Conversion(C)	2,842,638	-	-	Indirect

1-3 of 3 transactions

About Sealbond Ltd

Sealbond Ltd (SEC CIK 0002040446) files insider reports with the SEC as Director of Dogwood Therapeutics, Inc. (DWTX).

Signal8 holds 3 ownership filings by Sealbond Ltd (1 Form 3, 2 Form 4), filed between Oct 17, 2024 and Oct 27, 2026. Those filings report 3 transactions, from Nov 21, 2025 to Oct 26, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Sealbond Ltd's filings is in NEW TERRITORIES.

Recent filings by Sealbond Ltd

Oct 26, 2026: Grant or award of DWTX shares (Form 4, code A).
Nov 21, 2025: Conversions of DWTX shares (2 lines, Form 4, code C).

Other insiders filing for Dogwood Therapeutics, Inc. (DWTX)

De La Rosa Abel, Director
Thomas John C, Director
Whitley Richard James, Director
Keefer David R, Director
Grosswald Ralph, SVP OF OPERATIONS
Walsh Angela, Chief Financial Officer

How to read Form 4 transaction codes